Angiographic Findings of the Multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL)

• E. Regar

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• P.W. Serruys

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• C. Bode

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• C. Holubarsch

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• J.L. Guermonprez

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• W. Wijns

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• A. Bartorelli

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• C. Constantini

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• M. Degertekin

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• K. Tanabe

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• C. Disco

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• E. Wuelfert

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

• M.C. Morice

  From Thoraxcenter, Rotterdam, the Netherlands (E.R., P.W.S., M.D., K.T.); Medizinische Universitätsklinik, Freiburg, Germany (C.B., C.H.); Hôpital Broussais, Paris, France (J.L.G.); Onze Lieve Vrouw Klinik, Aalst, Belgium (W.W.); Centro Cardiologico, Milano, Italy (A.B.); Clinico Cardiologico, Curitibana, Parana, Brasil (C.C.); Cardialysis BV, Rotterdam, the Netherlands (C.D.); Cordis Corporation, Waterloo, Belgium (E.W.); and L’Institut Cardiovasculaire Paris-Sud, Massy, France (M.C.M.).

Bibliographic Information

Other Title

• Sirolimus-Eluting Stents Inhibit Restenosis Irrespective of the Vessel Size

Abstract

Background— Restenosis remains the major limitation of coronary catheter-based intervention. In small vessels, the amount of neointimal tissue is disproportionately greater than the vessel caliber, resulting in higher restenosis rates. In the Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) trial, ≈40% of the vessels were small (<2.5 mm). The present study evaluates the relationship between angiographic outcome and vessel diameter for sirolimus-eluting stents. Methods and Results— Patients were randomized to receive either an 18-mm bare metal Bx VELOCITY (BS group, n=118), or a sirolimus-eluting Bx VELOCITY stent (SES group, n=120). Subgroups were stratified into terciles according to their reference diameter (RD; stratum I, RD <2.36 mm; stratum II, RD 2.36 mm to 2.84 mm; stratum III, RD >2.84 mm). At 6-month follow-up, the restenosis rate in the SES group was 0% in all strata (versus 35%, 26%, and 20%, respectively, in the BS group). In-stent late loss was 0.01±0.25 versus 0.80±0.43 mm in stratum I, 0.01±0.38 versus 0.88±0.57 mm in stratum II, and −0.06±0.35 versus 0.74±0.57 mm in stratum III (SES versus BS). In SES, the minimal lumen diameter (MLD) remained unchanged (Δ −0.72 to 0.72 mm) in 97% of the lesions and increased (=late gain, ΔMLD <−0.72 mm) in 3% of the lesions. Multivariate predictors for late loss were treatment allocation ( P <0.001) and postprocedural MLD ( P = 0.008). Conclusions— Sirolimus-eluting stents prevent neointimal proliferation and late lumen loss irrespective of the vessel diameter. The classic inverse relationship between vessel diameter and restenosis rate was seen in the bare stent group but not in the sirolimus-eluting stent group.

Journal

• Circulation

  Circulation 106 (15), 1949-1956, 2002-10-08

  Ovid Technologies (Wolters Kluwer Health)

Keywords

• Physiology (medical)
• Cardiology and Cardiovascular Medicine

Details

• CRID: 1363107368726482176
• NII Article ID: 30022667781
• DOI: 10.1161/01.cir.0000034045.36219.12
• ISSN: 15244539
• ISSN: 00097322
• Web Site: https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000034045.36219.12
• Data Source:
  • Crossref
  • CiNii Articles